

PTO-1390  
(REV 12-29-99)

DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER

TRANSMITTAL LETTER TO THE UNITED STATES  
DESIGNATED/ELECTED OFFICE (DO/EO/US)  
CONCERNING A FILING UNDER 35 U.S.C. 371

701826-51150

U.S. APPLICATION NO. (If known, see 37 CFR 1.5)

09/719,737

PRIORITY DATE CLAIMED

17 June 1998

INTERNATIONAL APPLICATION NO.  
PCT/CA99/00572INTERNATIONAL FILING DATE  
17 June 1999

TITLE OF INVENTION ANTISENSE OLIGONUCLEOTIDES FOR TREATING OR PREVENTING ATOPIC DISEASES AND NEOPLASTIC CELL PROLIFERATION

APPLICANT(S) FOR DO/EO/US Paolo Renzi

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☐ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☒ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☐ This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. ☐ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☐ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
  - a. ☐ is transmitted herewith (required only if not transmitted by the International Bureau).
  - b. ☐ has been transmitted by the International Bureau.
  - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. ☐ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
  - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
  - b. ☐ have been transmitted by the International Bureau.
  - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
  - d. ☐ have not been made and will not be made.
8. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11. to 16. below concern document(s) or information included:

11. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☒ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☐ A FIRST preliminary amendment.
- ☐ A SECOND or SUBSEQUENT preliminary amendment.
14. ☐ A substitute specification.
15. ☐ A change of power of attorney and/or address letter.
16. ☒ Other items or information:

Executed Declaration/Power of Attorney  
Sequence Listing (6 pp.) & Diskette  
Response to Sequence Listing Requirement  
Statement Under 1.821(f)

Copy of Notification of Missing Requirements  
Copy of Notification to Comply with Requirements for Patent Applications containing Sequence Disclosures  
Check in the amount of \$65.00  
Check in the amount of \$40.00  
Certificate of Express Mail - Label No. EL 565094425 US

07/JUN/2001 UEDUVIJE 00000051 09719737

01 PCT:254

65.00 UP

19,737

PCT/CA99/00572

701826-51150

CALCULATIONS PTO USE ONLY

17. ☒ The following fees are submitted:

**BASIC NATIONAL FEE ( 37 CFR 1.492 (a) (1) - (5) ) :**

Neither international preliminary examination fee (37 CFR 1.482)  
nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO  
and International Search Report not prepared by the EPO or JPO ..... \$970.00  
International preliminary examination fee (37 CFR 1.482) not paid to  
USPTO but International Search Report prepared by the EPO or JPO ..... \$840.00  
International preliminary examination fee (37 CFR 1.482) not paid to USPTO but  
international search fee (37 CFR 1.445(a)(2)) paid to USPTO ..... \$690.00  
International preliminary examination fee paid to USPTO (37 CFR 1.482)  
but all claims did not satisfy provisions of PCT Article 33(1)-(4) ..... \$670.00  
International preliminary examination fee paid to USPTO (37 CFR 1.482)  
and all claims satisfied provisions of PCT Article 33(1)-(4) ..... \$96.00

**ENTER APPROPRIATE BASIC FEE AMOUNT =**

\$

Surcharge of \$130.00 for furnishing the oath or declaration later than ☐ 20 ☒ 30  
months from the earliest claimed priority date (37 CFR 1.492(e)).

\$ 65.00

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE
Total claims	- 20 =		X \$18.00
Independent claims	- 3 =		X \$78.00
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$260.00

\$  
\$  
\$  
\$

**TOTAL OF ABOVE CALCULATIONS =**

\$ 65.00

Reduction of 1/2 for filing by small entity, if applicable. A Small Entity Statement  
must also be filed (Note 37 CFR 1.9, 1.27, 1.28).

\$

**SUBTOTAL =**

\$ 65.00

Processing fee of \$130.00 for furnishing the English translation later than ☐ 20 ☐ 30  
months from the earliest claimed priority date (37 CFR 1.492(f)).

\$

**TOTAL NATIONAL FEE =**

\$

Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be  
accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property

\$ 40.00

**TOTAL FEES ENCLOSED =**

\$

Amount to be  
refunded: \$  
charged: \$

a. ☒ A check in the amount of \$ 65.00 & 40.00 to cover the above fees is enclosed.

b. ☐ Please charge my Deposit Account No. \_\_\_\_\_ in the amount of \$ \_\_\_\_\_ to cover the above fees.  
A duplicate copy of this sheet is enclosed.

c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any  
overpayment to Deposit Account No. 50-0850. A duplicate copy of this sheet is enclosed.

**NOTE:** Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR  
1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

David S. Resnick  
NIXON PEABODY LLP  
101 Federal Street  
Boston, MA 02110

SIGNATURE:

David S. Resnick

NAME

34,235

REGISTRATION NUMBER

#3

Practitioner's Docket No.: 701826-51150

## IN THE UNITED STATES RECEIVING OFFICE (RO/US)

09/719,737 17 June 1999 17 June 1998  
APPLICATION NO. INTERNATIONAL FILING DATE PRIORITY DATE CLAIMED

ANTISENSE OLIGONUCLEOTIDES FOR TREATING OR PREVENTING ATOPIC  
DISEASES AND NEOPLASTIC CELL PROLIFERATION TITLE OF INVENTION

Paolo Renzi  
APPLICANT(S)

Assistant Commissioner for Patents  
Washington, D.C. 20231

**VERIFIED CERTIFICATION OF EXPRESS MAILING DATE  
(INTERNATIONAL APPLICATION (37 C.F.R. SECTION 1.10(c)))**

I declare that, on June 29, 2001, I deposited, with the United States Postal Service, in an envelope "Express Mail, Post Office to Addressee," bearing Label Number EL 565094425 US, addressed to the "Assistant Commissioner for Patents, Washington, D.C. 20231," and having an express mail certification that I executed, the following papers:


A copy of these papers from the file of this application is attached.

Transmittal Letter to the DO/EO/US (2 pp.);  
Executed Declaration/ Power of Attorney (1 p.);  
Cover Sheet for Assignment in the EO/US (4 pp.);  
Executed Assignment (1 p.);  
Copy of Notification of Missing Requirements  
Copy of Notification to Comply with Requirements;  
Check in the amount of \$65.00;  
Check in the amount of \$40.00;  
Sequence Listing (6 pp.) and diskette;  
Response to Sequence Listing Requirement (1 p);  
Statement under 1.821 (f)  
Return Receipt postcard.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application of any patent issuing thereon.

Date: June 29, 2001

Zinna L. Mang  
(typed or printed name of person making this verified statement)

  
Signature of person making this verified statement

Practitioner's Docket No. 701826-51150

--

**IN THE UNITED STATES ELECTED OFFICE (EO/US)**

09/719,737	17 June 1999 (17.06.99)	17 June 1998 (17.06.98)
Application Number	International Filing Date	International Earliest Priority Date

TITLE OF INVENTION: ANTISENSE OLIGONUCLEOTIDES FOR TREATING OR PREVENTING  
ATOPIC DISEASES AND NEOPLASTIC CELL PROLIFERATION

APPLICANT: Renzi, Paolo

**Box PCT**  
**Assistant Commissioner for Patents**  
**Washington, D.C. 20231**  
**ATTENTION: EO/US**

---

**CERTIFICATION UNDER 37 C.F.R. section 1.10\***  
(Express Mail label number is *mandatory*.)  
(Express Mail certification is *optional*.)

I hereby certify that this paper, along with any document referred to, is being deposited with the United States Postal Service on this date June 29, 2001, in an envelope as "Express Mail Post Office to Addressee," mailing Label Number EL 565094425 US, addressed to the: Assistant Commissioner for Patents, Washington, D.C. 20231.

Zinna Mang  
(type or print name of person mailing paper)  
Zinna J. Mang  
Signature of person mailing paper

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Paolo Renzi  
SERIAL NO.: 09/719,737 GROUP: -  
Filed: June 17, 1999 EXAMINER: Vonda M. Wallace  
FOR: ANTISENSE OLIGONUCLEOTIDES FOR TREATING  
OR PREVENTING ATOPIC DISEASES AND NEOPLASTIC  
CELL PROLIFERATION

ASSISTANT COMMISSIONER FOR PATENTS  
WASHINGTON, DC 20231

Sir:


## RESPONSE TO SEQUENCE LISTING REQUIREMENT

In response to the Notice to Comply with the Sequence Listing Requirements mailed April 30, 2001, a copy of which is attached hereto, Applicant encloses herewith a paper copy and a computer readable form of the "Sequence Listing" and a statement that the content of the paper and computer readable copies are the same and does not contain new matter.

The Commissioner is hereby authorized to charge any additional fees associated with this communication to Deposit Account No. 50-0820.

Respectfully submitted,

Date: 6/29/01



David S. Resnick (Reg. No. 34,235)  
Nixon Peabody LLP  
101 Federal Street  
Boston, Massachusetts 02110-1832  
(617) 345-6057

Encl.: - Pages 1 to 6 of the Sequence Listing;  
- Computer-readable form of the Sequence Listing; and  
- Statement.

09/719,737-052501

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

**Paolo Renzi**

For: **ANTISENSE OLIGONUCLEOTIDES FOR TREATING OR  
PREVENTING ATOPIC DISEASES AND NEOPLASTIC CELL  
PROLIFERATION**

Filed: **June 17, 1999**

Serial No.: **09/719,737**

Examiner: **Vonda M. Wallace**

The Commissioner of Patents  
and Trademarks  
Washington, D.C. 20231  
U.S.A.

**STATEMENT UNDER 1.821(f)**

Sir:

In connection with this Application a Computer Readable Copy of the Information required under 1.821 is being submitted concurrently together with the specification pages preceding the claims.

As required under 1.821(f), the undersigned hereby states that the content of the paper copy which comprises the General Information and the Sequence Listings and the Computer Readable Copy are the same and does not contain new matter.

This statement is made by a person registered to practice before the U.S. Patent and Trademark Office and as such, a verified statement is not required and is not being submitted.

Respectfully,

By: 

Christian Cawthorn  
Reg. No. 47,352  
Tel.: (514) 847-4256

Date: June 27, 2001

09719737-062901